- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07740044
Medical Large Language Model-Assisted Diagnosis and Treatment in Primary Care Chronic Disease Management
27 de julho de 2026 atualizado por: Jiangsu Taizhou People's Hospital
Verification and Application Study of Medical Large Language Model-Assisted Diagnosis and Treatment in Primary Care Chronic Disease Management: A Randomized Controlled Study
This study aims to explore the feasibility of using medical large language models to assist in chronic disease management.
By setting up experimental and control group interventions and having experts blindly evaluate anonymized cases, it compares different management approaches in chronic disease care, verifying the scientific basis, effectiveness, and potential for broader use of medical large language models in supporting chronic disease management.
Visão geral do estudo
Status
Ainda não está recrutando
Intervenção / Tratamento
Tipo de estudo
Intervencional
Inscrição (Estimado)
20
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Contato de estudo
- Nome: Guoyu Wang, MD
- Número de telefone: +8615951154720
- E-mail: wangguoyutzheart@163.com
Locais de estudo
-
-
Jiangsu
-
Taizhou, Jiangsu, China, 225300
- The Affiliated Taizhou People's Hospital of Nanjing Medical University
-
Contato:
- Guoyu Wang, MD
- Número de telefone: +8615951154720
- E-mail: wangguoyutzheart@163.com
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Não
Descrição
Inclusion Criteria:
- Work experience of 3 years or more;
- Able to complete the case assessment tasks required by the study;
- Have a practicing doctor qualification;
- Work at a township health center or community health service center;
- Voluntarily participate in the study and sign the informed consent form.
Exclusion Criteria:
N/A
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Outro
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: LLM-Assisted Intervention Group
Primary care doctors creating management plans for chronic diseases (coronary heart disease, atrial fibrillation, heart failure, stroke) with the help of large medical language models
|
The primary care physicians in the intervention group completed the management decisions for chronic disease cases, including disease assessment, examination suggestions, treatment plans, selection of management methods, and health education, with the assistance of the medical LLM.
|
|
Sem intervenção: Usual Care Control Group
Primary care doctors creating management plans for chronic diseases (coronary heart disease, atrial fibrillation, heart failure, stroke) without the help of a large medical language model
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
expert overall scores
Prazo: through study completion, an average of 3 months.
|
A total of 200 cases (50 each of coronary heart disease, atrial fibrillation, heart failure, and stroke) were grouped by disease type and independently evaluated in a blinded manner by three subspecialty experts.
For each case, the two management plans were anonymized in the same way and then randomly labeled by a computer as Plan A and Plan B. Experts could only view the anonymized case information and the two corresponding anonymized management plans.
They rated them using a Likert scale on several aspects: accuracy of condition assessment, reasonableness of test recommendations, reasonableness of treatment plans, appropriateness of management choices, scientific nature of patient education content, feasibility at the primary care level, overall clinical quality.
Experts were instructed to rank the seven dimensions from lowest to highest quality.
These ordinal rankings were then converted into standardized scores of 1 to 5. Higher scores mean better.
|
through study completion, an average of 3 months.
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
accuracy of condition assessment
Prazo: through study completion, an average of 3 months.
|
A total of 200 cases (50 each of coronary heart disease, atrial fibrillation, heart failure, and stroke) were grouped by disease type and independently evaluated in a blinded manner by three subspecialty experts.
For each case, the two management plans were anonymized in the same way and then randomly labeled by a computer as Plan A and Plan B. Experts could only view the anonymized case information and the two corresponding anonymized management plans.
They rated them using a Likert scale on accuracy of condition assessment from lowest to highest quality.
These ordinal rankings were then converted into standardized scores of 1 to 5. Higher scores mean better.
|
through study completion, an average of 3 months.
|
|
reasonableness of test recommendations
Prazo: through study completion, an average of 3 months.
|
A total of 200 cases (50 each of coronary heart disease, atrial fibrillation, heart failure, and stroke) were grouped by disease type and independently evaluated in a blinded manner by three subspecialty experts.
For each case, the two management plans were anonymized in the same way and then randomly labeled by a computer as Plan A and Plan B. Experts could only view the anonymized case information and the two corresponding anonymized management plans.
They rated them using a Likert scale regarding the reasonableness of test recommendations.
Experts were instructed to rank the dimension from lowest to highest quality.
These ordinal rankings were then converted into standardized scores of 1 to 5. Higher scores mean better.
|
through study completion, an average of 3 months.
|
|
reasonableness of treatment plans
Prazo: through study completion, an average of 3 months.
|
A total of 200 cases (50 each of coronary heart disease, atrial fibrillation, heart failure, and stroke) were grouped by disease type and independently evaluated in a blinded manner by three subspecialty experts.
For each case, the two management plans were anonymized in the same way and then randomly labeled by a computer as Plan A and Plan B. Experts could only view the anonymized case information and the two corresponding anonymized management plans.
They rated them using a Likert scale regarding the reasonableness of treatment plans.
Experts were instructed to rank the dimension from lowest to highest quality.
These ordinal rankings were then converted into standardized scores of 1 to 5. Higher scores mean better.
|
through study completion, an average of 3 months.
|
|
appropriateness of management choices
Prazo: through study completion, an average of 3 months.
|
A total of 200 cases (50 each of coronary heart disease, atrial fibrillation, heart failure, and stroke) were grouped by disease type and independently evaluated in a blinded manner by three subspecialty experts.
For each case, the two management plans were anonymized in the same way and then randomly labeled by a computer as Plan A and Plan B. Experts could only view the anonymized case information and the two corresponding anonymized management plans.
They rated them using a Likert scale regarding the ppropriateness of management choices.
Experts were instructed to rank the dimension from lowest to highest quality.
These ordinal rankings were then converted into standardized scores of 1 to 5. Higher scores mean better.
|
through study completion, an average of 3 months.
|
|
scientific nature of patient education content
Prazo: through study completion, an average of 3 months.
|
A total of 200 cases (50 each of coronary heart disease, atrial fibrillation, heart failure, and stroke) were grouped by disease type and independently evaluated in a blinded manner by three subspecialty experts.
For each case, the two management plans were anonymized in the same way and then randomly labeled by a computer as Plan A and Plan B. Experts could only view the anonymized case information and the two corresponding anonymized management plans.
They rated them using a Likert scale regarding the scientific nature of patient education content.
Experts were instructed to rank the dimension from lowest to highest quality.
These ordinal rankings were then converted into standardized scores of 1 to 5. Higher scores mean better.
|
through study completion, an average of 3 months.
|
|
feasibility at the primary care level
Prazo: through study completion, an average of 3 months.
|
A total of 200 cases (50 each of coronary heart disease, atrial fibrillation, heart failure, and stroke) were grouped by disease type and independently evaluated in a blinded manner by three subspecialty experts.
For each case, the two management plans were anonymized in the same way and then randomly labeled by a computer as Plan A and Plan B. Experts could only view the anonymized case information and the two corresponding anonymized management plans.
They rated them using a Likert scale regarding the feasibility at the primary care level.
Experts were instructed to rank the dimension from lowest to highest quality.
These ordinal rankings were then converted into standardized scores of 1 to 5. Higher scores mean better.
|
through study completion, an average of 3 months.
|
|
the overall clinical quality
Prazo: through study completion, an average of 3 months.
|
A total of 200 cases (50 each of coronary heart disease, atrial fibrillation, heart failure, and stroke) were grouped by disease type and independently evaluated in a blinded manner by three subspecialty experts.
For each case, the two management plans were anonymized in the same way and then randomly labeled by a computer as Plan A and Plan B. Experts could only view the anonymized case information and the two corresponding anonymized management plans.
They rated them using a Likert scale regarding the overall clinical quality.
Experts were instructed to rank the dimension from lowest to highest quality.
These ordinal rankings were then converted into standardized scores of 1 to 5. Higher scores mean better.
|
through study completion, an average of 3 months.
|
|
risk advice
Prazo: through study completion, an average of 3 months.
|
A total of 200 cases (50 each of coronary heart disease, atrial fibrillation, heart failure, and stroke) were grouped by disease type and independently evaluated in a blinded manner by three subspecialty experts.
For each case, the two management plans were anonymized in the same way and then randomly labeled by a computer as Plan A and Plan B. Experts could only view the anonymized case information and the two corresponding anonymized management plans.
If there is no risk advice, the expert selects 'No'; otherwise, the expert selects 'Yes' and specifically lists the content of the risk advice.
|
through study completion, an average of 3 months.
|
|
Any diagnostic or treatment information missing
Prazo: through study completion, an average of 3 months.
|
A total of 200 cases (50 each of coronary heart disease, atrial fibrillation, heart failure, and stroke) were grouped by disease type and independently evaluated in a blinded manner by three subspecialty experts.
For each case, the two management plans were anonymized in the same way and then randomly labeled by a computer as Plan A and Plan B. Experts could only view the anonymized case information and the two corresponding anonymized management plans.
If there is no omission of diagnostic and treatment information, the expert selects "No"; otherwise, the expert selects "Yes" and specifically lists the omitted diagnostic and treatment content.
|
through study completion, an average of 3 months.
|
|
feedback regarding the use of medical LLM by primary care physicians
Prazo: through study completion, an average of 3 months.
|
After primary care physicians complete a case assessment assisted by medical LLM , they will fill out an evaluation of the medical LLM usage, including whether the medical LLM helped in disease assessment, assisted in formulating examination plans, aided in developing treatment plans, improved chronic disease management capabilities, supported chronic disease education, assisted in management approach selection, enhanced confidence, saved time, whether there were hallucinations or omissions, whether it provided risky suggestions, and any additional comments on the use of the medical LLM.
|
through study completion, an average of 3 months.
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Estimado)
17 de agosto de 2026
Conclusão Primária (Estimado)
30 de setembro de 2026
Conclusão do estudo (Estimado)
30 de novembro de 2026
Datas de inscrição no estudo
Enviado pela primeira vez
20 de julho de 2026
Enviado pela primeira vez que atendeu aos critérios de CQ
27 de julho de 2026
Primeira postagem (Real)
31 de julho de 2026
Atualizações de registro de estudo
Última Atualização Postada (Real)
31 de julho de 2026
Última atualização enviada que atendeu aos critérios de controle de qualidade
27 de julho de 2026
Última verificação
1 de julho de 2026
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Distúrbios Cerebrovasculares
- Doenças Cerebrais
- Doenças do Sistema Nervoso Central
- Doenças do Sistema Nervoso
- Doenças Vasculares
- Doenças cardiovasculares
- Processos Patológicos
- Doenças cardíacas
- Arritmias Cardíacas
- Arteriosclerose
- Doenças Arteriais Oclusivas
- Doença cardíaca
- Isquemia do miocárdio
- Condições Patológicas, Sinais e Sintomas
- Derrame
- Insuficiência cardíaca
- Fibrilação atrial
- Doença arterial coronária
Outros números de identificação do estudo
- LSKY 2026-114-01
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
NÃO
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Não
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .